Human papillomavirus vaccines

Affiliations

¹ Centre for Immunization and Respiratory Infectious Diseases (Ismail), Public Health Agency of Canada, Ottawa, Ont.; Metro City Medical Clinic (Ismail); Immunization and Vaccine Preventable Diseases (Deeks), Public Health Ontario; Dalla Lana School of Public Health (Deeks), University of Toronto, Toronto, Ont. shainoor.ismail@canada.ca shainoor.ismail@gmail.com.
² Centre for Immunization and Respiratory Infectious Diseases (Ismail), Public Health Agency of Canada, Ottawa, Ont.; Metro City Medical Clinic (Ismail); Immunization and Vaccine Preventable Diseases (Deeks), Public Health Ontario; Dalla Lana School of Public Health (Deeks), University of Toronto, Toronto, Ont.

Review

Shainoor J Ismail et al. CMAJ. 2017.

. 2017 Sep 25;189(38):E1212.

doi: 10.1503/cmaj.150465.

¹ Centre for Immunization and Respiratory Infectious Diseases (Ismail), Public Health Agency of Canada, Ottawa, Ont.; Metro City Medical Clinic (Ismail); Immunization and Vaccine Preventable Diseases (Deeks), Public Health Ontario; Dalla Lana School of Public Health (Deeks), University of Toronto, Toronto, Ont. shainoor.ismail@canada.ca shainoor.ismail@gmail.com.
² Centre for Immunization and Respiratory Infectious Diseases (Ismail), Public Health Agency of Canada, Ottawa, Ont.; Metro City Medical Clinic (Ismail); Immunization and Vaccine Preventable Diseases (Deeks), Public Health Ontario; Dalla Lana School of Public Health (Deeks), University of Toronto, Toronto, Ont.

No abstract available

Conflict of interest statement

Competing interests: None declared.

1. Updated recommendations on human papillomavirus (HPV) vaccines: 9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization. Ottawa: Public Health Agency of Canada; 2016. Available: www.canada.ca/en/public-health/services/publications/healthy-living/9-va... (accessed 2017 Apr. 30). - PubMed
1. Gooi Z, Chan JY, Fakhry C. The epidemiology of the human papillomavirus related to oropharyngeal head and neck cancer. Laryngoscope 2016;126:894–900. - PubMed
1. Update on human papillomavirus (HPV) vaccines. Can Commun Dis Rep 2012;38:1–62. Available: www.phac-aspc.gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-1/index-eng.php (accessed 2017 Apr. 30). - PMC - PubMed
1. Safety of HPV vaccines: extract from report of GACVS meeting of 2–3 December 2015, published in the WHO Weekly Epidemiological Record of January 22, 2016. Geneva: World Health Organization; 2016. Available: www.who.int/vaccine_safety/committee/topics/hpv/Dec_2015/en/ (accessed 2017 Apr. 30).
1. IOM (Institute of Medicine). Adverse effects of vaccines: evidence and causality. Stratton K, Ford A, Rusch E, et al., editors. Washington: National Academies Press; 2012:505–21. Available: www.nap.edu/catalog/13164/adverse-effects-of-vaccines-evidence-and-causa... (accessed 2017 Jan. 30). - PubMed